X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES VENUS REMEDIES ALKEM LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x - -898.2 - View Chart
P/BV x 7.7 0.3 2,930.0% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALKEM LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
VENUS REMEDIES
Mar-16
ALKEM LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,589218 728.9%   
Low Rs1,23282 1,500.6%   
Sales per share (Unadj.) Rs417.5365.6 114.2%  
Earnings per share (Unadj.) Rs56.31.5 3,788.3%  
Cash flow per share (Unadj.) Rs64.737.9 170.6%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.9382.5 76.6%  
Shares outstanding (eoy) m119.5711.44 1,045.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.4 823.3%   
Avg P/E ratio x25.1101.0 24.8%  
P/CF ratio (eoy) x21.84.0 550.9%  
Price / Book Value ratio x4.80.4 1,227.5%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6531,717 9,825.0%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m9,171324 2,827.2%   
Avg. sales/employee Rs ThNM4,100.7-  
Avg. wages/employee Rs ThNM318.0-  
Avg. net profit/employee Rs ThNM16.7-  
INCOME DATA
Net Sales Rs m49,9154,183 1,193.4%  
Other income Rs m1,64520 8,184.6%   
Total revenues Rs m51,5614,203 1,226.8%   
Gross profit Rs m8,482812 1,045.1%  
Depreciation Rs m1,006417 241.3%   
Interest Rs m671380 176.6%   
Profit before tax Rs m8,45135 24,076.9%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60618 8,872.9%   
Profit after tax Rs m6,73117 39,595.3%  
Gross profit margin %17.019.4 87.6%  
Effective tax rate %19.051.6 36.9%   
Net profit margin %13.50.4 3,317.9%  
BALANCE SHEET DATA
Current assets Rs m27,0622,771 976.7%   
Current liabilities Rs m15,3241,931 793.4%   
Net working cap to sales %23.520.1 117.2%  
Current ratio x1.81.4 123.1%  
Inventory Days Days67125 53.2%  
Debtors Days Days4154 76.8%  
Net fixed assets Rs m12,6105,328 236.6%   
Share capital Rs m239114 209.0%   
"Free" reserves Rs m34,4904,177 825.7%   
Net worth Rs m35,0274,376 800.4%   
Long term debt Rs m1,2121,911 63.4%   
Total assets Rs m54,3878,428 645.3%  
Interest coverage x13.61.1 1,245.1%   
Debt to equity ratio x00.4 7.9%  
Sales to assets ratio x0.90.5 184.9%   
Return on assets %13.64.7 289.1%  
Return on equity %19.20.4 4,947.1%  
Return on capital %24.96.6 376.6%  
Exports to sales %12.90-   
Imports to sales %3.120.5 15.0%   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540858 179.5%   
Fx inflow Rs m6,5630-   
Fx outflow Rs m3,012858 350.9%   
Net fx Rs m3,552-858 -413.8%   
CASH FLOW
From Operations Rs m7,259469 1,548.3%  
From Investments Rs m1,86429 6,384.2%  
From Financial Activity Rs m-9,273-464 2,000.6%  
Net Cashflow Rs m-15035 -434.8%  

Share Holding

Indian Promoters % 66.9 32.9 203.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.2 18,388.9%  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 66.4 -  
Shareholders   68,381 20,121 339.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 16, 2018 03:35 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - SHASUN PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS